Gelteq Launches First Veterinary Clinical Trial for Antiparasitic Drug, Targets 2026 FDA Application
GELS is trading near its 52-week low of $0.389 (0.5% above the low) on light trading volume (0.3× avg).
Summary
Gelteq Ltd. has commenced its first clinical trial for an antiparasitic drug candidate, marking a significant expansion into the veterinary pharmaceutical sector. This trial aims to support an FDA regulatory pathway for animal use, with the company targeting a potential application later in 2026. This development builds on the FDA's prior acceptance of Gelteq's suitability petition and follows the recent securing of up to $3.5 million in debt financing, which the company states provides sufficient capital to execute its dual-track strategy. For a micro-cap biotech, this represents a material step forward in product development and market diversification, validating its proprietary technology. Traders will closely monitor the trial's progress and any updates regarding the FDA submission.
At the time of this announcement, GELS was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.39 to $3.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.